Endocrinology Research Analysis
Q1 2026 endocrinology coalesced around controllable nutrient flux and organ gateway biology, anchored by transporter-centric mitochondrial mechanisms (SLC25A45, SLC25A35) and intestinal/lymphatic routes for glucose and lipid handling (aPKC–GLUT1 and GPR182). Tissue-selective endocrine pharmacology advanced via adipocyte-specific sclerostin loop3–LRP4 targeting, while an endothelial IRE1α–THBS1 checkpoint linked vascular adaptation to islet support. Precision hepatology progressed with a sex-spec
Summary
Q1 2026 endocrinology coalesced around controllable nutrient flux and organ gateway biology, anchored by transporter-centric mitochondrial mechanisms (SLC25A45, SLC25A35) and intestinal/lymphatic routes for glucose and lipid handling (aPKC–GLUT1 and GPR182). Tissue-selective endocrine pharmacology advanced via adipocyte-specific sclerostin loop3–LRP4 targeting, while an endothelial IRE1α–THBS1 checkpoint linked vascular adaptation to islet support. Precision hepatology progressed with a sex-specific GPR110–ERα axis explaining female-biased MASH risk. Methodologically, a human NKX2.2–CLEC16A/endosomal platform enabled pharmacologic rescue in autoimmune-like T1D. Conceptually, neuroimmune control of reproduction (microglial RANK→GnRH) and ERV-driven chimeric RNAs (MLT2A1) expanded the quarter’s endocrine scope across neurobiology and early human development.
Selected Articles
1. Mitochondrial control of fuel switching via carnitine biosynthesis.
SLC25A45 is identified as the mitochondrial trimethyllysine carrier essential for carnitine biosynthesis; its loss depletes carnitine, impairs fatty acid oxidation, and forces carbohydrate reliance, defining a core mechanism of metabolic flexibility.
Impact: Unveils a previously unknown mitochondrial transporter that governs carnitine pools and fuel selection, with sweeping implications for fatty acid oxidation disorders and dietary/metabolic interventions.
Clinical Implications: Therapeutically modulating SLC25A45 or downstream carnitine synthesis may correct FAO defects and improve metabolic flexibility in MASLD and related conditions.
Key Findings
- SLC25A45 functions as the mitochondrial trimethyllysine carrier enabling carnitine biosynthesis.
- Loss of SLC25A45 depletes cellular carnitine and impairs mitochondrial fatty acid oxidation.
- Metabolism shifts toward carbohydrate reliance when SLC25A45 is absent.
2. Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.
The study shows that sclerostin’s loop3 interaction with adipocyte LRP4 drives dyslipidemia and dysglycemia and that selective loop3–LRP4 blockade in adipocytes reverses metabolic defects while sparing bone-directed loop2 effects.
Impact: Defines a tissue-selective, epitope-level therapeutic concept that decouples skeletal and metabolic effects of a bone-derived hormone, offering a safer path than existing anti-sclerostin strategies.
Clinical Implications: Loop3–LRP4–selective inhibitors could improve glucose and lipid profiles without bone-related liabilities, warranting first-in-human development.
Key Findings
- Serum sclerostin is elevated in osteoporosis with T2DM and in new-onset T2DM.
- Sclerostin loop3 drives whole-body lipid and glucose metabolic impairment in vivo.
- Adipocyte-specific loop3–LRP4 blockade reverses metabolic defects while sparing loop2-mediated bone effects.
3. Mitochondrial control of glycerolipid synthesis by a PEP shuttle.
SLC25A35 is a mitochondrial PEP exporter that supports glyceroneogenesis; hepatic inhibition in obese mice alleviated steatosis and improved glucose homeostasis.
Impact: Reveals a druggable mitochondrial node that couples carbon flux to hepatic lipid synthesis with in vivo therapeutic proof-of-concept for MASLD.
Clinical Implications: Modulating SLC25A35 may offer a novel class of MASLD therapeutics that re-route carbon flux without broadly suppressing lipid metabolism.
Key Findings
- SLC25A35 mediates pH-dependent mitochondrial PEP export.
- PEP export supports glyceroneogenesis and hepatic glycerolipid synthesis.
- Liver-specific inhibition reduces steatosis and improves systemic glucose homeostasis in obese mice.
4. Atypical protein kinase C activation drives intestinal glucose excretion in diabetes mellitus.
Preclinical data demonstrate that activating intestinal aPKC promotes GLUT1-mediated uptake of circulating glucose and its luminal excretion, nominating a druggable, non-renal pathway for glucose lowering and potential weight loss.
Impact: Defines an organ-gateway mechanism for systemic glucose disposal distinct from SGLT2 inhibition or bariatric surgery.
Clinical Implications: If translated, aPKC/GLUT1 modulators could inaugurate a new class of glucose-lowering and weight-loss agents that leverage intestinal excretion.
Key Findings
- aPKC activation induces transcriptional signatures of intestinal glucose excretion.
- GLUT1-mediated uptake and luminal excretion are increased without proliferative signaling.
- Pharmacologic and genetic activation elevates intestinal glucose excretion in vivo.
5. Endogenous retroviruses synthesize heterologous chimeric RNAs to reinforce human early embryo development.
Human embryo work shows ERV MLT2A1-derived chimeric RNAs recruit RNA polymerase II via HNRNPU to drive global ZGA; MLT2A1 depletion impairs ZGA and development.
Impact: Demonstrates ERV-driven chimeric RNAs as active regulators of human ZGA, reframing transposable elements as core developmental effectors with IVF biomarker potential.
Clinical Implications: Enables development of embryo-competence biomarkers and conceptually supports safe, targeted modulation of ERV-driven transcription in reproductive medicine.
Key Findings
- Embryos arrested at the eight-cell ZGA stage show down-regulation of ERV MLT2A1.
- MLT2A1 depletion reduces ZGA gene expression and causes developmental failure.
- MLT2A1-derived chimeric RNAs recruit RNA polymerase II via HNRNPU to amplify ZGA.
6. GPR182 is a lipoprotein receptor for dietary fat absorption.
Loss or antibody blockade of lymphatic endothelial GPR182 prevents chylomicron entry into lacteals, limiting intestinal lipid absorption and protecting against diet-induced obesity in mice.
Impact: Introduces a druggable lymphatic gateway for dietary fat with in vivo antibody proof-of-concept, opening a non-intestinal-epithelium route for anti-obesity therapy.
Clinical Implications: Anti-GPR182 biologics could complement incretin-based weight-loss agents by reducing fat uptake; human studies must assess fat-soluble nutrient handling and long-term safety.
Key Findings
- GPR182 mediates chylomicron transport into lacteals on lymphatic endothelium.
- Blockade impairs lipid absorption, elevates HDL, and protects against diet-induced obesity.
- Ultrastructural imaging shows failed chylomicron entry without GPR182.
7. Endothelial IRE1α promotes thrombospondin-1 mRNA decay and supports metabolic stress adaptation of pancreatic islets.
Endothelial IRE1α degrades THBS1 mRNA via RNase activity to relieve anti-angiogenic pressure, enabling intra-islet angiogenesis and β-cell functional support during metabolic stress.
Impact: Links endothelial ER-stress signaling to endocrine adaptation, nominating a vascular target to preserve islet function in obesity/diabetes.
Clinical Implications: Therapeutic modulation of the IRE1α–THBS1 axis could enhance islet revascularization and insulin secretory capacity as an adjunct to metabolic therapies.
Key Findings
- Endothelial IRE1α deletion impairs insulin secretion and glucose tolerance in high-fat diet mice.
- Loss of endothelial IRE1α blunts intra-islet angiogenesis and compensatory islet growth.
- IRE1α RNase activity promotes THBS1 mRNA decay in islet endothelium.
8. Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis.
Microglial RANK signaling is required for normal GnRH neuron activity; its depletion causes hypogonadotropic hypogonadism via impaired GnRH neuronal function.
Impact: Introduces a neuroimmune regulator of reproductive endocrinology with high conceptual impact and translational potential.
Clinical Implications: Positions microglial RANK as a candidate biomarker/target for central hypogonadism, motivating genetic and CSF-biomarker studies.
Key Findings
- Microglial RANK signaling is necessary for GnRH neuron function.
- Microglial Rank depletion induces hypogonadotropic hypogonadism via impaired GnRH activity.
- Defines a neuroimmune-to-neuron regulatory pathway affecting the HPG axis.
9. Single-cell multi-omic analyses highlight the essential role of NKX2.2-CLEC16A/endosomal pathway for human pancreatic differentiation and function.
A human stem-cell platform maps endocrine lineage programs and identifies an essential NKX2.2–CLEC16A/endosomal axis; CLEC16A knockout models autoimmune-like T1D and enables discovery of pharmacologic rescuers.
Impact: Delivers an intervention-ready human model and mechanistic blueprint to preserve or restore beta-cell differentiation/function in autoimmune diabetes.
Clinical Implications: Enables target discovery and early translational testing for agents that rescue CLEC16A-related defects and support beta-cell preservation.
Key Findings
- Single-cell transcriptome/chromatin dynamics define endocrine bifurcation networks.
- An essential NKX2.2–CLEC16A/endosomal pathway is required for human pancreatic endocrine differentiation.
- CLEC16A knockout produces an autoimmune-like human T1D model and identifies pharmacologic rescuers.
10. Hepatic GPR110 contributes to sex disparity in the development of MASH through oestrogen receptor α-dependent signalling.
Hepatocyte-specific loss of Gpr110 protects female but not male mice from diet-induced MASH; a human GPR110 variant associates with higher MASLD prevalence in women, with effects dependent on hepatic ERα.
Impact: Defines a sex-aware, druggable hepatic GPCR mechanism with genetic support, enabling precision stratification and female-focused therapeutic strategies in MASH.
Clinical Implications: Supports genotyping-informed risk stratification in women and development of ERα-dependent GPR110 modulators as female-preferential MASH therapies.
Key Findings
- Hepatocyte Gpr110 deletion protects female but not male mice from MASH.
- Human GPR110 variant rs937057 associates with higher MASLD prevalence in women.
- Protective phenotype depends on hepatic ERα signaling.